SAN FRANCISCO, CA—At ACC.13, the American College of Cardiology’s 62 nd Annual Scientific Session, leading cardiologists presented that the use of dabigatran following ablation for atrial fibrillation ...

The analysis involved stratification of the RE-LY trial patients by whether or not they had a previous stroke or TIA. The goal was to demonstrate whether history of stroke or TIA affected the overall ...

“The results we have seen from RE-DUAL PCI™ are another great piece of evidence on the benefit Pradaxa ® can offer patients with atrial fibrillation and their treating physicians; a benefit which has ...

Demonstrated to significantly reduce stroke compared to warfarin, Pradaxa is first new oral anticoagulant approved by the FDA in more than 50 years RIDGEFIELD, Conn., Oct. 19 /PRNewswire/ -- The U.S.

Dabigatran linked to lower incidence of bleeding events in atrial fibrillation Anticoagulation with dabigatran was associated with fewer bleeding complications compared with warfarin among patients ...

(HealthDay News) — In clinical practice, patients starting dabigatran therapy do not have significantly different rates of ischemic stroke or extracranial hemorrhage than those starting warfarin ...

The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial compared the efficacy and safety of dabigatran (Pradax in Canada and Pradaxa in Europe), a new oral direct thrombin ...

RIDGEFIELD, Conn., March 19, 2017 /PRNewswire/ -- Important new data from the RE-CIRCUIT® study show a better safety profile for Pradaxa® (dabigatran etexilate mesylate) compared to warfarin in atrial ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA has announced approval of ...

For more than 60 years, warfarin was the only FDA-approved oral anticoagulation widely available for stroke prevention in patients with AF. Despite the effectiveness of warfarin, several limitations ...

INGELHEIM, Germany-- (BUSINESS WIRE)--The RE-DUAL PCI™ trial explored anticoagulation with Pradaxa ® (dabigatran etexilate) dual therapy without aspirin in non-valvular atrial fibrillation (AF) ...